Search

Your search keyword '"Urotensins metabolism"' showing total 281 results

Search Constraints

Start Over You searched for: Descriptor "Urotensins metabolism" Remove constraint Descriptor: "Urotensins metabolism"
281 results on '"Urotensins metabolism"'

Search Results

151. Neuropeptide interactions and REM sleep: a role for Urotensin II?

152. Solution structure of urotensin-II receptor extracellular loop III and characterization of its interaction with urotensin-II.

153. Increased gene expression of urotensin II-related peptide in the hearts of rats with congestive heart failure.

154. Liberation of urotensin II from the teleost urophysis: an historical overview.

155. Nonpeptide Urotensin-II receptor agonists and antagonists: review and structure-activity relationships.

156. Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11).

157. Behavioral actions of urotensin-II.

158. Hemodynamic-independent anti-natriuretic effect of urotensin II in spontaneously hypertensive rats.

159. Urotensin-II and cardiovascular remodeling.

160. [Orn5]URP acts as a pure antagonist of urotensinergic receptors in rat cortical astrocytes.

161. Comparative understanding of UTS2 and UTS2R genes for their involvement in type 2 diabetes mellitus.

162. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats.

163. Urotensin II: a cardiovascular and renal update.

164. Seasonal changes in CRF-I and urotensin I transcript levels in masu salmon: correlation with cortisol secretion during spawning.

165. Prediction of structure of G-protein coupled receptors and of bound ligands, with applications for drug design.

166. Urotensin II in cardiovascular regulation.

167. [Urotensin II promotes atherosclerosis].

168. [The role of urotensin II in human pathophysiology].

169. Phenylpiperidine-benzoxazinones as urotensin-II receptor antagonists: synthesis, SAR, and in vivo assessment.

170. Evaluation of no-wash calcium assay kits: enabling tools for calcium mobilization.

171. Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes.

172. Therapeutic potential of blockade of the urotensin II system in systemic hypertension.

173. Definition of new pharmacophores for nonpeptide antagonists of human urotensin-II. Comparison with the 3D-structure of human urotensin-II and URP.

174. Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.

175. Role of urotensin II and its receptor in health and disease.

176. Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction.

177. Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol.

178. Urotensin-II and its receptor (UT-R) are expressed in rat brain endothelial cells, and urotensin-II via UT-R stimulates angiogenesis in vivo and in vitro.

179. Urotensin-II and cardiovascular diseases.

180. Biochemical and functional characterization of high-affinity urotensin II receptors in rat cortical astrocytes.

181. The effects of urotensin-II on proliferation of pheochromocytoma cells and mRNA expression of urotensin-II and its receptor in pheochromocytoma tissues.

182. Renal and vascular actions of urotensin II.

183. Haplotypes in the urotensin II gene and urotensin II receptor gene are associated with insulin resistance and impaired glucose tolerance.

184. Caudal neurosecretory system of the zebrafish: ultrastructural organization and immunocytochemical detection of urotensins.

185. Urotensin-II and UII-receptor expression and function in the rat adrenal cortex.

186. Diabetic nephropathy: from mechanisms to rational therapies.

187. Identification and characterization of binding sites for human urotensin-II in Sprague-Dawley rat renal medulla using quantitative receptor autoradiography.

188. [The role of urotensin II in airway remodeling of asthma].

189. Characterization of urotensin-II receptor structural domains involved in the recognition of U-II, URP, and urantide.

190. Inhalation of nebulized nitroglycerin, a nitric oxide donor, for the treatment of pulmonary hypertension induced by high pulmonary blood flow.

191. The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.

192. Renal effects of human urotensin-II in rats with experimental congestive heart failure.

193. [Change and clinical implication of urotensin II in plasma and induced sputum of chronic obstructive pulmonary disease].

194. Alteration of vascular urotensin II receptor in mice with apolipoprotein E gene knockout.

195. Localization of the urotensin II receptor in the rat central nervous system.

196. [Expression of Urotensin II and its receptor on right ventricle in rats of pulmonary hypertension].

197. [Effects of oxidized-low density lipoprotein on expression of urotensin II receptor GPR14 in rat aortic smooth muscle cells].

198. [Acute coronary syndrome in patients with chronic kidney disease--risk stratification].

199. A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker.

200. CRF-related peptides contribute to stress response and regulation of appetite in hypoxic rainbow trout.

Catalog

Books, media, physical & digital resources